BioSpace News Archive

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases, announced an update to its September conference calendar.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.

BioInvent International AB announces the enrollment of the first patient in a Phase 1/2 trial in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, investigating a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206, in solid tumors.

Zealand Pharma A/S announced that it will host an Obesity R&D Event in London on December 5, 2023 with management and external scientific experts in obesity.

Kodiak Sciences Inc. announced that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m. Eastern Time.

Verge Genomics today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

Plus Therapeutics, Inc. today announced it has expanded its supply agreement with Biocept by acquiring an option to exclusively license Biocept’s CNSide, a CSF-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy.

Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.

Polarean, a commercial-stage medical device leader in advanced magnetic resonance imaging of the lungs, announced it has partnered with VIDA Diagnostics, a clinical imaging intelligence company providing medical imaging software solutions which manage the complexities of digital biomarkers.